The global breast cancer screening tests industry, valued at USD 2.1 billion in 2023, is set to achieve significant growth, reaching USD 4.4 billion by 2033, according to recent market projections. This robust growth trajectory reflects a CAGR of approximately 7.8% over the forecast period (2023–2033).
Globally, digital mammography has supplanted traditional film-based mammography. Digital mammography has advantages such as improved image quality, quicker image storage and retrieval, and the possibility of computer-aided detection (CAD) systems assisting radiologists in interpretation.
Imaging technologies, such as 3D mammography (tomosynthesis), have advanced in the breast cancer screening test market, providing more comprehensive images and reducing false-positive findings. Other developing technologies are being investigated for improved accuracy and patient experience, such as contrast-enhanced mammography and automated breast ultrasonography.
Biomarker testing, in addition to imaging-based screening assays, is significant in breast cancer screening. Biomarkers, such as BRCA gene mutations and specific protein markers (e.g., HER2, hormone receptors), aid in determining a person’s risk of getting breast cancer and guiding treatment recommendations.
Regulatory agencies, such as the United States Food and Drug Administration (FDA), are critical in authorizing and regulating breast cancer screening tests to assure their safety and efficacy. Compliance with regulatory regulations is required for screening test market entry and commercialization.
Key Takeaways from Market Study:
- Among diagnostic test type, imaging tests accounts for USD 1.1 billion in 2022 owed to its potential for computer-aided detection (CAD) systems to assist radiologists in interpretation.
- Hospitals held more than 3% of the global market share in 2022. This can be attributed to the fact that the majority of the world’s population suffers from diseases that, with skilled assistance, can be appropriately detected in the hospital setting.
- By region, North America held dominant share in world in 2022. The U.S. leads in this region with high prevalence of breast cancer and high requirement of breast cancer screening devices.
- East Asia is set to provide lucrative opportunities for players while growing at an expected growth rate of 5% CAGR over the forecast period.
“The growing cancer burden and increasing adoption of non-invasive treatment contribute to higher demand of breast cancer screening tests.” says an analyst of Future Market Insights.
Heightened Market Interest: Our Complete Report Delivers Extensive Analysis and Trends!
Market Competition:
The breast cancer screening test market is highly competitive, with key players including Ion Beam and Sumitomo Heavy Industries. These companies are constantly participating partnerships, award competition with their products and launching new products to gain a larger market share, with a focus on affordability, convenience, and effectiveness.
- June, 2023, Heligenics, a cutting-edge biotech startup, has announced the development of a first precise genetic test for choosing among breast cancer medicines.
Key Companies Profiled:
- AstraZeneca
- Novartis
- Sanofi
- Pfizer
- Bayer AG
- GlaxoSmithKline plc
- Siemens Healthineers
- Hologic Inc.
- General Electric Company
- Koninklijke Philips NV
- Fujifilm Holdings
- A&G Pharmaceutical, Inc.
- Biocrates Life Sciences AG
- Metabolomic Technologies, Inc.
Key Market Segments Covered in the Breast Cancer Screening Test Industry Research:
By Diagnostics Test Type:
- Blood Marker Tests
- Imaging Test
- Mammography
- MRI screening test
- Molecular Breast Imaging Test
- PET scan
- Ultrasound
- Genetic Test
- Fluorescence In Situ Hybridization
- HER gene test
- Immunohistochemistry Test
By End User:
- Hospitals
- Diagnostic Centres
- Cancer Institutes
- Research Laboratories
By Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-347-918-3531
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube